Literature DB >> 16503855

Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.

Brigette B Y Ma1, Anthony T C Chan.   

Abstract

Nasopharyngeal carcinoma (NPC) is endemic in Asia and is etiologically associated with the Epstein-Barr virus. Although radiotherapy can cure most patients with early-stage disease, those with advanced disease often develop recurrences following radiotherapy. The past decade has witnessed significant advances in the systemic treatment of advanced NPC. This article reviews the latest literature regarding: combined modality therapy for locoregionally advanced NPC; clinical trials of novel biologic and cytotoxic therapies for metastatic NPC; and disease monitoring with the plasma Epstein-Barr virus DNA assay.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16503855     DOI： 10.1586/14737140.6.3.383

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  11 in total

1.  Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors.

Authors:  Mukul Prasad; Sashigala Ponnalagu; Qun Zeng; Khang Luu; Si Min Lang; Hiu Yi Wong; Man Si Cheng; Meihui Wu; Karthik Mallilankaraman; Radoslaw Mikolaj Sobota; Yan Ting Lim; Loo Chien Wang; Chuan Keng Goh; Kai Xun Joshua Tay; Kwok Seng Loh; Cheng-I Wang; Wen-Hsien Lee; Boon Cher Goh; Chwee Ming Lim; Herbert Schwarz
Journal:  Cancer Immunol Immunother       Date:  2022-03-17       Impact factor: 6.630

2.  Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis.

Authors:  Luc Friboulet; Catherine Pioche-Durieu; Sandrine Rodriguez; Alexander Valent; Sylvie Souquère; Hugues Ripoche; Abdelmajid Khabir; Sai Wah Tsao; Jacques Bosq; Kwok Wai Lo; Pierre Busson
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

3.  Functional characterization of TRPM7 in nasopharyngeal carcinoma and its knockdown effects on tumorigenesis.

Authors:  Yi Qin; Zhi-Wei Liao; Jing-Yan Luo; Wen-Zhe Wu; An-Shang Lu; Pu-Xia Su; Bing-Quan Lai; Xiao-Xiao Wang
Journal:  Tumour Biol       Date:  2016-01-15

4.  The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.

Authors:  Brigette B Y Ma; Vivian W Y Lui; Edwin P Hui; Cecilia P Y Lau; Kakiu Ho; Margaret H L Ng; S H Cheng; Sai-Wah Tsao; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2009-05-27       Impact factor: 3.850

5.  The Super-scan and Flare Phenomena in a Nasopharyngeal Cancer Patient: A Case Report.

Authors:  Min-Chuan Lu; Tzyy-Ling Chuang; Moon-Sing Lee; Wen-Yen Chiou; Hon-Yi Lin; Shih-Kai Hung
Journal:  J Clin Med Res       Date:  2012-05-15

6.  CFTR is a potential marker for nasopharyngeal carcinoma prognosis and metastasis.

Authors:  Ziwei Tu; Qu Chen; Jie Ting Zhang; Xiaohua Jiang; Yunfei Xia; Hsiao Chang Chan
Journal:  Oncotarget       Date:  2016-11-22

7.  Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis.

Authors:  Mei Lan; Chunyan Chen; Ying Huang; Li Tian; Zhijun Duan; Fei Han; Junfang Liao; Meiling Deng; Terence T Sio; Anussara Prayongrat; Lie Zheng; Shaoxiong Wu; Taixiang Lu
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

Review 8.  Estimating the global burden of Epstein-Barr virus-related cancers.

Authors:  Yide Wong; Michael T Meehan; Scott R Burrows; Denise L Doolan; John J Miles
Journal:  J Cancer Res Clin Oncol       Date:  2021-10-27       Impact factor: 4.553

9.  A new approach for cellular immunotherapy of nasopharyngeal carcinoma.

Authors:  Corey Smith; Rajiv Khanna
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

10.  Impact of Neoadjuvant Chemotherapy on the Administration of Concurrent Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma.

Authors:  Benjamin Maas; Cheryl Ho; Sarah Hamilton; Doug Leedy; Eric Berthelet
Journal:  Cureus       Date:  2018-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.